Upgrade to SI Premium - Free Trial

H.C. Wainwright Reiterates Buy Rating on Rani Therapeutics (RANI)

October 6, 2026 7:07 AM
H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $11.00 price target on Rani Therapeutics (NASDAQ: RANI).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments